MSL presentation example: a slide-by-slide walkthrough
This is a worked example of an MSL interview presentation, twelve slides built around ATLAS-1, a hypothetical phase III trial in second-line metastatic disease. Every figure here is illustrative; the structure, timing, and reasoning are what transfer to your own therapeutic area. For each slide you'll find what goes on it, why it scores, and the mistake that costs candidates the round.
"Present a recent pivotal trial in your therapeutic area in 15 minutes, followed by 15 minutes of questions." That's the standard MSL assignment. The panel is typically the hiring manager, a Medical Advisor or Director, and often someone from HR, so the deck has to hold a scientific audience and a non-scientific one at the same time.
Trial name (ATLAS-1, a hypothetical phase III in second-line metastatic disease), your name, the date, and a one-line framing question: "Does adding compound X to standard of care change second-line outcomes?"
Why it works: The framing question tells the panel you understand the clinical question before the data. It also gives you a thread to return to on the final slide.
Common pitfall: A title slide with a company logo and nothing else. It wastes the one moment the room is fully attentive.
2
Agenda in three beats
Clinical context → the trial → what it means in practice. Fifteen seconds, no reading aloud.
Why it works: Signals structure. Panels score structure explicitly, and a three-beat agenda tells them you can run a KOL meeting to time.
Common pitfall: Seven agenda items. It reads as a data dump rather than a narrative.
3
Unmet need
One chart of current second-line outcomes, one sentence naming the specific patient segment left behind, and the size of that segment.
Why it works: MSL work starts from unmet need, not from the asset. Leading here shows the panel you think like a clinician.
Common pitfall: Generic epidemiology. Panels want the gap, not the prevalence.
4
Mechanism and rationale
A single clean pathway diagram, the target, and two sentences on why hitting it should matter in this population. Preclinical or phase II signal in one line.
Why it works: This is the slide where scientific depth is judged. A clean diagram you can talk around beats a dense one you read from.
Common pitfall: A borrowed publication figure with eight labelled nodes you never mention.
Why it works: Panels probe design more than results. Being able to defend stratification choices and endpoint selection is the differentiator.
Common pitfall: Design and results on one slide. It forces the panel to split attention exactly when you need it on the design.
6
Baseline characteristics
A trimmed table, five or six rows that matter clinically, with the two imbalances flagged in colour.
Why it works: Flagging your own imbalances before the panel does is the single fastest way to build credibility.
Common pitfall: The full publication table at 8pt. Nobody reads it, and it hides the imbalance you should be owning.
7
Primary endpoint
One Kaplan–Meier curve, hazard ratio with confidence interval, p-value, median difference, and the number at risk visible.
Why it works: This is the slide the panel remembers. One number said out loud, the HR and its CI, is what they'll quote back to you.
Common pitfall: Stacking secondary endpoints on the same slide and diluting the headline.
8
Key secondaries and subgroups
Forest plot with two or three pre-specified subgroups called out, and an explicit note on which were exploratory.
Why it works: Distinguishing pre-specified from exploratory unprompted demonstrates the scientific discipline compliance teams care about.
Common pitfall: Presenting a post-hoc subgroup as if it were a finding. It's the most common single reason candidates lose the round.
9
Safety
Grade 3+ adverse events side by side, discontinuation rates, and one line on the adverse event that will actually shape prescribing behaviour.
Why it works: Balance. A candidate who presents efficacy without proportional safety reads as promotional, the fastest disqualifier in Medical Affairs.
Common pitfall: A safety slide added at the end because you knew you needed one.
10
Limitations
Three limitations, stated plainly: open-label design, short follow-up for overall survival, under-representation of one patient group.
Why it works: Volunteering limitations converts the Q&A from interrogation to discussion. It also pre-empts the panel's opening question.
Common pitfall: Omitting the slide, or listing limitations so trivial they read as evasion.
11
What this means in practice
Who the data changes management for, what a KOL will push back on, and the two open questions you'd take into field conversations.
Why it works: This is the Medical Affairs slide. It's where you stop being a presenter of a paper and start sounding like the MSL for the asset.
Common pitfall: Ending on the results. Panels consistently mark down decks with no translation to practice.
12
Close and questions
Return to the framing question from slide 1, answer it in one sentence, then open the floor.
Why it works: The callback makes a 15-minute deck feel like an argument rather than a sequence. It's the last thing scored.
Common pitfall: A "Thank you" slide. It ends the narrative on nothing.
How this deck maps to the scorecard
Most MSL panels score four dimensions. This structure deliberately front-loads evidence for each one.
Scientific depth, slides 4–8, and specifically your ability to defend design choices unprompted.
Balance and compliance, slides 9–10. Proportional safety and volunteered limitations are what separate medical from promotional.
Audience calibration, the whole deck, judged on whether the HR panellist followed slides 3 and 11.
Field relevance, slide 11 alone. Candidates who skip it rarely progress, however strong the science.
Q&A: the five questions this deck invites
"Why do you think the control arm underperformed versus historical data?"
"Would you have chosen a different primary endpoint?"
"How would you handle a KOL who dismisses the subgroup finding?"
"What would you want to see in a confirmatory study?"
"How would you brief the commercial team on this without stepping over the line?"
Prepare a 60-second answer for each. Rehearse them standing, out loud, on camera, the Q&A carries as much weight as the deck itself.
Make your CV as sharp as your deck
PharmaReady scores your CV, cover letter, and interview answers against the actual Medical Affairs role you're applying to, so the story your deck tells and the story your CV tells are the same one.